Live Breaking News & Updates on இஂக்மர் ொேர்ர்

Stay informed with the latest breaking news from இஂக்மர் ொேர்ர் on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in இஂக்மர் ொேர்ர் and stay connected to the pulse of your community

Covid vaccine from Germany's CureVac just 48% effective: final results

Covid vaccine from Germany's CureVac just 48% effective: final results
thebangladeshtoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thebangladeshtoday.com Daily Mail and Mail on Sunday newspapers.

Germany , United-states , America , German , Ingmar-hoerr , Franz-werner-haas , Pfizer , European-union , European-medicines-agency , ஜெர்மனி , ஒன்றுபட்டது-மாநிலங்களில் , அமெரிக்கா

Impfung gegen Tumore: "Die Vision: Nicht mehr an Krebs zu sterben"

pocket
„Es ist eine Vision – aber ich bin sehr zuversichtlich“, sagt Wolfgang Hilbe, Leiter der 1. Med. Abteilung (Zentrum für Onkologie und Hämatologie) in der Klinik Ottakring in Wien - und meint die Entwicklung von Impfstoffen gegen Krebs, die so funktionieren könnten. Hilbe erklärt, wie so eine Therapie ablaufen könnte:
Bei einem Patienten wird ein Tumor diagnostiziert, er wird operiert, Tumorzellen werden an eine mRNA-Impfstoff-Firma geschickt.
Dort werden die typischen Merkmale an der Oberfläche der Krebszellen (Proteine bzw. Proteinteile) identifiziert. Mit einem Computerprogramm werden die Zielstrukturen ermittelt, bei denen die Wahrscheinlichkeit hoch ist, dass sie durch das Immunsystem erkannt werden.

Ottakring , Wien , Austria , United-states , Vienna , Hungary , Hungarians , Austrian , Ingmar-hoerr , Christoph-huber , Immunologe-christoph-huber , Ugur-sahin

Germany's CureVac Covid vaccine only 48% effective

Germany's CureVac Covid vaccine only 48% effective
Thu, Jul 01, 2021
FRANKFURT: Germany´s CureVac said Wednesday that final trial results showed its coronavirus vaccine had an efficacy rate of just 48 percent, far lower than those developed by mRNA rivals BioNTech/Pfizer and Moderna.
The outcome had been expected after poor interim data were released earlier this month.
The company in part blamed "the unprecedented context of 15 strains circulating" among the trial volunteers, as well as varying responses across age groups.
The Covid vaccines developed by Germany´s BioNTech in partnership with US giant Pfizer and by US firm Moderna -- based on the same novel messenger RNA technology -- were approved earlier on in the pandemic after showing around 95 percent efficacy.

Germany , United-states , America , German , Donald-trump , Ingmar-hoerr , Dietmar-hopp , Franz-werner-haas , Pfizer , European-union , European-medicines-agency , President-donald-trump

Covid Vaccine From Germany's CureVac Just 48% Effective

Covid Vaccine From Germany's CureVac Just 48% Effective
By Michelle FITZPATRICK
06/30/21 AT 7:58 PM
Germany's CureVac said Wednesday that final trial results showed its coronavirus vaccine had an efficacy rate of just 48 percent, far lower than those developed by mRNA rivals BioNTech/Pfizer and Moderna.
The outcome had been expected after poor interim data were released earlier this month.
The company in part blamed "the unprecedented context of 15 strains circulating" among the trial volunteers, as well as varying responses across age groups.
The Covid vaccines developed by Germany's BioNTech in partnership with US giant Pfizer and by US firm Moderna -- based on the same novel messenger RNA technology -- were approved earlier on in the pandemic after showing around 95 percent efficacy.

Germany , United-states , America , German , Donald-trump , Ingmar-hoerr , Dietmar-hopp , Franz-werner-haas , Pfizer , European-union , European-medicines-agency , President-donald-trump

COVID vaccine from Germany's CureVac just 48% effective – final results

' + activeFrame.title + ' '); $(".fotorama-caption").addClass("add_caption"); $(".fotorama-caption").removeClass("remove_caption"); } else { // alert("hide div"); $(".fotorama-caption").addClass("remove_caption"); $(".fotorama-caption").removeClass("add_caption"); } }) .fotorama(); COVID vaccine from Germany's CureVac just 48% effective – final results Wednesday, June 30, 2021 FRANKFURT, Germany (AFP)— Germany's CureVac announced Wednesday that final trial results showed its coronavirus vaccine had an efficacy rate of just 48 per cent, far lower than those developed by mRNA rivals BioNTech and Moderna. The outcome had been expected after poor interim results were released earlier this month. The company in part blamed "the unprecedented context of 15 strains circulating" among the trial volunteers, as well as varying responses across different age groups.

Germany , United-states , America , German , Ingmar-hoerr , Franz-werner-haas , Pfizer , European-union , European-medicines-agency , ஜெர்மனி , ஒன்றுபட்டது-மாநிலங்களில் , அமெரிக்கா

Covid vaccine from Germany´s CureVac just 48% effective

Covid vaccine from Germany´s CureVac just 48% effective
By
Thursday Jul 01, 2021
FRANKFURT: Germany´s CureVac said Wednesday that final trial results showed its coronavirus vaccine had an efficacy rate of just 48 percent, far lower than those developed by mRNA rivals BioNTech/Pfizer and Moderna.
The outcome had been expected after poor interim data were released earlier this month.
The company in part blamed "the unprecedented context of 15 strains circulating" among the trial volunteers, as well as varying responses across age groups.
The Covid vaccines developed by Germany´s BioNTech in partnership with US giant Pfizer and by US firm Moderna -- based on the same novel messenger RNA technology -- were approved earlier on in the pandemic after showing around 95 percent efficacy.

Germany , United-states , America , German , Donald-trump , Ingmar-hoerr , Dietmar-hopp , Franz-werner-haas , Pfizer , European-union , European-medicines-agency , President-donald-trump

Covid Vaccine From Germanys CureVac Just 48% Effective

Covid vaccine from Germany's CureVac just 48% effective
Thu 01st July 2021 | 08:50 AM
Frankfurt, (UrduPoint / Pakistan Point News - 1st Jul, 2021 ) :Germany's CureVac said Wednesday that final trial results showed its coronavirus vaccine had an efficacy rate of just 48 percent, far lower than those developed by mRNA rivals BioNTech/Pfizer and Moderna.
The outcome had been expected after poor interim data were released earlier this month.
The company in part blamed "the unprecedented context of 15 strains circulating" among the trial volunteers, as well as varying responses across age groups.
The Covid vaccines developed by Germany's BioNTech in partnership with US giant Pfizer and by US firm Moderna -- based on the same novel messenger RNA technology -- were approved earlier on in the pandemic after showing around 95 percent efficacy.

Germany , United-states , America , German , Donald-trump , Ingmar-hoerr , Dietmar-hopp , Franz-werner-haas , Pfizer , European-union , European-medicines-agency , Pakistan-point-news

COVID-19 vaccine from Germany's CureVac just 48% effective

COVID-19 vaccine from Germany's CureVac just 48% effective
euractiv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from euractiv.com Daily Mail and Mail on Sunday newspapers.

Germany , United-states , America , German , Donald-trump , Ingmar-hoerr , Dietmar-hopp , Franz-werner-haas , Pfizer , European-union , European-medicines-agency , European-commission

Covid vaccine from Germany's CureVac just 48 percent effective

Covid vaccine from Germany's CureVac just 48 percent effective
thelocal.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelocal.de Daily Mail and Mail on Sunday newspapers.

Germany , United-states , America , German , Donald-trump , Ingmar-hoerr , Dietmar-hopp , Franz-werner-haas , Pfizer , European-union , European-medicines-agency , President-donald-trump

CureVac disappoints in pivotal final trial of COVID-19 vaccine with 48 percent efficacy

CureVac disappoints in pivotal final trial of COVID-19 vaccine with 48 percent efficacy
wionews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wionews.com Daily Mail and Mail on Sunday newspapers.

Germany , German , Donald-trump , Ingmar-hoerr , Dietmar-hopp , Franz-werner-haas , Pfizer , Astrazeneca , European-union , European-medicines-agency , Johnson , President-donald-trump